[Translation] Phase I clinical study on the safety and pharmacokinetics of recombinant humanized anti-PD-L1 monoclonal antibody LP002 injection in the treatment of advanced digestive system tumors

1)评价LP002单药对晚期消化系统肿瘤的安全性、有效性； 2)评价LP002联合顺铂+氟尿嘧啶方案对晚期胃癌的安全性、有效性； 3)初步评估LP002联合围手术期化疗顺铂+氟尿嘧啶方案治疗PD-L1表达阳性的局部晚期可切除胃癌的有效性； 4)评价LP002联用溶瘤病毒OH2治疗以消化系统肿瘤为主的晚期实体瘤的安全性、有效性； 5)观察LP002的PK及ADA特征。

[Translation]

1) Evaluate the safety and efficacy of LP002 alone in the treatment of advanced digestive system tumors; 2) Evaluate the safety and efficacy of LP002 combined with cisplatin + fluorouracil in the treatment of advanced gastric cancer; 3) Preliminary evaluation of the efficacy of LP002 combined with perioperative chemotherapy cisplatin + fluorouracil in the treatment of locally advanced resectable gastric cancer with positive PD-L1 expression; 4) Evaluate the safety and efficacy of LP002 combined with oncolytic virus OH2 in the treatment of advanced solid tumors, mainly digestive system tumors; 5) Observe the PK and ADA characteristics of LP002.

Start Date12 Jun 2019

Sponsor / Collaborator

Taizhou Houde Aoke Technology Co. Ltd.

100 Clinical Results associated with Oncolytic Herpes Simplex Virus Type 2

100 Translational Medicine associated with Oncolytic Herpes Simplex Virus Type 2

100 Patents (Medical) associated with Oncolytic Herpes Simplex Virus Type 2

Literatures (Medical) associated with Oncolytic Herpes Simplex Virus Type 2

01 Jul 2024·Virology

VP5 protein of oncolytic herpes simplex virus type 2 induces apoptosis in A549 cells through TP53I3 protein

Article

Author: Wang, Xinya ; Liu, Binlei ; Xia, Wen ; Zhao, Xiaotong ; Hu, Han ; Wu, Jian ; Ren, Xinxin ; Zhang, Hui ; Yang, Jingru ; Li, Le ; Zhou, Qin ; Wang, Yang

Oncolytic virotherapy stands out as a burgeoning and promising therapeutic paradigm, harnessing the intrinsic cytotoxicity of oncolytic viruses for selective replication and dissemination within tumors. The primary mode of action revolves around the direct eradication of tumor cells. In our previous investigations, we formulated an oncolytic herpes simplex virus type 2 (OH2) and substantiated its anti-tumor efficacy both in vivo and in vitro. Subsequently, we embarked on a phase I/II clinical trial in China (NMPA, 2018L02743) and the USA (FDA, IND 27137) to assess OH2's safety, biodistribution, and anti-tumor activity as a standalone agent in patients with advanced solid tumors. In this investigation, our primary focus was to comprehend the influence of the major capsid protein VP5 of OH2 on its efficacy as an antitumor agent. Our findings underscore that the VP5 protein significantly amplifies OH2's oncolytic impact on A549 cells. Additionally, we observed that VP5 actively promotes the induction of apoptosis in A549 cells, both in vivo and in vitro. Through comprehensive transcriptional sequencing, we further authenticated that the VP5 protein triggers apoptosis-related signaling pathways and Gene Ontology (GO) terms in A549 cells. Moreover, we scrutinized differentially expressed genes in the p53-dependent apoptosis pathway and conducted meticulous in vitro validation of these genes. Subsequently, we delved deeper into unraveling the functional significance of the TP53I3 gene and conclusively affirmed that the VP5 protein induces apoptosis in A549 cells through the TP53I3 gene. These revelations illuminate the underlying mechanisms of OH2's antitumor activity and underscore the pivotal role played by the VP5 protein. The outcomes of our study harbor promising implications for the formulation of effective oncolytic virotherapy strategies in cancer treatment.

100 Deals associated with Oncolytic Herpes Simplex Virus Type 2

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	CN	Hubei University of Technology	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Oncolytic Herpes Simplex Virus Type 2

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation